Product category:
Clinical chemistry analysis
News Release from: Ipsogen
Edited by the Laboratorytalk Editorial
Team on 07 September 2007
In vitro diagnostic tests for breast
cancer
Ipsogen can now offer DNAVision's microarray profiling services at the level of quality of quantitative PCR, the industry gold standard
Ipsogen, a molecular diagnostic company based in France and Connecticut, has signed an agreement with DNAVision, a provider of pharmacogenomic services in Europe Ipsogen gains the capability to offer its portfolio of breast cancer profiling tests to institutions and patients in a Clia/ISO17025 certified environment
This article was originally published on Laboratorytalk on 18 Sep 2007 at 8.00am (UK)
Related stories
Diagnostic products based on NPM1 mutations
Recent discovery by Falini and Mecucci at Institute of Hematology, University of Perugia, showed that about 60% of adult AML with normal karyotype have a mutation in the nucleophosmin (NPM1) gene
Accurate quantification of Jak2 V617F mutation
Ipsogen has developed a range of molecular assays based on mutations in the Jak2 gene, to which the company has worldwide exclusive intellectual property rights
"This agreement with DNAVision enables Ipsogen to launch a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies" said Vincent Fert, president and CEO of Ipsogen.
"DNAVision microarray testing facilities have the most advanced quality standards in Europe.
"This agreement definitely positions Ipsogen as a technology leader in diagnostic gene profiling" added Jean-Marc Le Doussal, Ipsogen director of breast cancer programme.
"We are delighted to combine our quality gene expression services with the genomic signatures discovered and validated by Ipsogen.
"With this agreement, we enter in a new era where microarrays are used as diagnostic tools" said Jean-Pol Detiffe, CEO of DNAVision.
"This agreement is a new evidence that DNAVision becomes the technical partner of choice for biotech companies who want to step into the diagnostic market without facing long IVD application procedures but with the help a quality certified service provider generating data available for clinical and diagnostic purposes", added Michael Herman, DNAVision, business development director.
Ipsogen has developed in collaboration with leading academic institutions expert in cancer care a range of microarray-based genomic signatures to characterise tumours and guide treatment options in breast cancer.
• Ipsogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
